Physician profile
Justine Fenner Biederman
NPI 1376040469
$6,802.55
in general payments reported to CMS, 2019-2025
26 companies · $2,967 in 2025
The $2,967 reported for 2025 was more than what 80% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $246 · 2023: $655 · 2024: $2,810 · 2025: $2,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,025 · Honoraria: $400 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,025.04 |
| Honoraria | $400.00 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,089.86 | 2024-2025 | |
| Incyte Corporation | $857.39 | 2023-2025 | Opzelura, Opzelura |
| Abbvie INC. | $719.87 | 2023-2025 | |
| Pfizer INC. | $626.95 | 2024-2025 | |
| Nobelpharma America, LLC | $522.95 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $483.17 | 2023-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $395.43 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $284.75 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $242.71 | 2022-2023 | Sotyktu |
| Organon LLC | $225.79 | 2025 | Vtama |
| Lilly USA, LLC | $216.29 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $193.10 | 2025 | Nemluvio |
| Dermavant Sciences, INC. | $157.53 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.41 | 2024-2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.91 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $97.52 | 2024-2025 | Filsuvez |
| Novartis Pharmaceuticals Corporation | $77.95 | 2023-2024 | |
| Lnhc, INC | $76.57 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $70.56 | 2024-2025 | Adbry |
| Verrica Pharmaceuticals INC. | $68.08 | 2023-2024 | Ycanth |
| Ucb, INC. | $27.40 | 2024 | Bimzelx |
| Genentech USA, INC. | $27.27 | 2024 | Xolair |
| Alexion Pharmaceuticals, INC. | $24.96 | 2025 | Koselugo |
| Sun Pharmaceutical Industries INC. | $24.80 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $15.49 | 2025 | Dupixent |
| Pierre Fabre Pharmaceuticals, INC. | $13.84 | 2024 | Hemangeol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justine Biederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.